Financial Reports Latest Updates Industry Maps Economic Calendar

Editas Medicine, Inc. (EDIT) Annual Reports

Q: Where can I read Editas Medicine, Inc. (EDIT) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Editas Medicine, Inc. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1650664 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$11.9M	$3.6M	+232.3%
Operating income	$-18.6M	$-51.5M	+64.0%
Net income	$-18.2M	$-53.2M	+65.8%
EPS (diluted)	$-0.15	$-0.63	+76.2%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 11.9 mn Net income -18.2 mn

Show table：Income statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	—	6.05	0.68	3.10	6.28	3.67	3.93	7.37	14.5	6.12	2.07	2.33	3.85	12.3	5.72	10.8	62.8	11.4	6.50	0.38	6.20	12.5	6.77	6.36	0.04	6.54	9.85	2.89	5.34	60.0	1.14	0.51	0.06	30.6	4.66	3.58	7.54	24.7	2.83	11.9
Operating income	-12.7	-5.16	-10.4	-7.38	-12.4	-17.8	-19.2	-21.2	-39.0	-30.6	-26.1	-26.8	-36.4	-31.6	-39.7	-16.3	-26.3	-31.3	-35.6	-34.6	-39.4	-46.6	-31.3	8.99	-65.9	-56.9	-55.4	-39.3	-41.6	-50.8	-54.2	-57.5	-63.5	-51.0	-44.1	-50.2	-24.0	-67.0	-71.9	-65.7	-46.6	-76.2	-51.5	-24.6	-7.75	-25.0	-18.6
Net income	-13.7	-5.29	-47.6	-7.40	-12.6	-17.7	-19.0	-21.0	-39.4	-31.1	-26.4	-26.6	-36.2	-30.9	-38.7	-15.2	-25.1	-29.3	-33.8	-32.9	-37.8	-37.7	-23.6	7.82	-62.5	-56.7	-55.3	-39.1	-41.4	-50.5	-53.5	-55.7	-60.7	-49.0	-40.3	-45.0	-18.9	-62.0	-67.6	-62.1	-45.4	-76.1	-53.2	-25.1	-5.62	-25.0	-18.2

Balance sheet

Quarterly · In mn (USD)

Total assets 237 mn Total liabilities 132 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	145	232	221	203	187	354	328	298	332	363	348	343	375	347	324	339	464	425	610	507	419	632	616	568	507	497	461	427	357	324	441	359	341	306	286	271	289	225	183	177	164	128	218
Total assets	—	—	—	—	149	249	250	242	229	395	369	339	373	404	394	388	420	379	356	372	509	467	655	597	573	780	756	717	677	623	581	531	514	464	542	505	499	440	385	328	342	264	211	202	187	149	237
Current liabilities	—	—	—	—	6.93	10.2	13.7	13.8	33.1	50.3	48.7	29.5	36.7	31.0	24.0	26.1	35.9	41.0	72.9	66.8	60.0	68.9	68.2	54.8	58.2	64.0	66.0	50.9	46.9	36.5	36.4	42.3	60.1	57.2	54.5	58.6	63.2	66.5	74.3	72.3	77.2	73.1	65.9	61.8	46.3	39.8	68.4
Total liabilities	—	—	—	—	32.6	47.5	62.3	72.0	94.6	189	184	161	165	156	162	163	184	162	163	162	246	232	229	156	179	142	143	130	124	110	115	116	154	147	142	144	150	146	153	152	207	201	191	188	159	145	132
Equity	-15.3	—	—	—	-83.1	201	187	170	135	206	185	178	208	248	231	224	236	217	193	210	262	235	427	441	394	638	613	587	554	513	465	415	361	317	400	360	349	294	232	176	134	62.4	19.2	13.4	27.3	4.41	105

Cash flow

Quarterly · In mn (USD)

Operating -29.6 mn Investing -29.8 mn Financing 118 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-8.65	-5.94	20.4	-11.9	-8.01	-9.63	-9.90	-17.0	-13.7	69.8	-26.2	-28.0	-25.1	-22.5	-16.7	-7.84	1.33	-29.0	-25.8	-26.9	41.0	-54.1	-30.9	-54.8	-40.1	-49.5	-39.0	-40.8	-34.6	-49.2	-37.8	-48.0	-42.3	-35.8	-38.7	-35.5	-22.2	-49.9	-57.1	-52.6	-50.8	-47.8	-50.2	-30.8	-36.4	-23.1	-29.6
Investing	-1.22	-0.3	-0.53	-0.19	-0.4	-2.56	-1.16	-0.71	0.96	-0.66	-181	-28.9	26.7	40.8	-71.7	-13.6	-8.60	50.6	76.1	-122	7.82	46.5	74.2	-152	-109	3.24	4.79	-39.7	-22.8	56.4	-4.00	89.2	-27.5	23.3	13.0	-103	62.8	-4.74	52.0	84.0	31.0	56.4	42.6	39.6	0.06	0.06	-29.8
Financing	18.5	0.79	22.0	120	-3.75	98.2	-0.49	-0.02	-0.54	97.1	-0.31	-0.73	58.5	52.7	2.67	1.24	30.4	1.53	2.37	43.4	84.6	3.05	211	0.82	9.10	261	17.1	2.50	1.06	0.22	0.37	0.08	0.62	0	118	0	0.51	0.19	0.32	0	55.5	-1.44	7.41	17.2	17.3	0	118
Cash at period end	10.6	5.17	47.0	155	143	229	218	200	185	352	144	86.5	147	218	132	112	135	158	211	105	238	233	486	280	140	355	338	260	204	211	169	211	142	129	221	82.5	124	69.2	64.4	95.8	132	139	139	166	147	124	182

Profitability

Quarterly · %

Operating margin -156.1% Net margin -153.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	-644.0%	-4490.8%	-843.2%	-425.8%	-993.8%	-803.6%	-537.9%	-112.0%	-429.0%	-1511.0%	-1530.0%	-898.9%	-320.9%	-814.5%	-291.6%	14.3%	-576.9%	-875.3%	-14617.7%	-633.4%	-333.7%	-749.5%	-852.5%	-136952.4%	-970.7%	-517.3%	-1527.3%	-940.1%	-39.9%	-5902.3%	-14016.2%	-107649.2%	-152.2%	-1635.1%	-1440.6%	-325.4%	-31.3%	-883.2%	-156.1%
Net margin	—	—	—	—	—	—	—	—	-650.5%	-4559.7%	-853.7%	-423.4%	-986.9%	-787.9%	-525.3%	-105.0%	-409.4%	-1413.7%	-1450.0%	-856.1%	-307.5%	-659.2%	-219.3%	12.4%	-547.3%	-872.9%	-14579.4%	-630.7%	-332.3%	-746.0%	-840.2%	-132681.0%	-929.3%	-497.8%	-1395.6%	-843.7%	-31.4%	-5458.1%	-13178.8%	-101870.5%	-148.3%	-1633.5%	-1487.8%	-333.0%	-22.7%	-882.4%	-153.3%

Returns & leverage

Quarterly · %

ROE -118.8% ROA -33.0% Debt ratio 55.6%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	-42.4%	-30.3%	-41.4%	-377.5%	-54.2%	-63.4%	-71.0%	-70.2%	-52.9%	-63.6%	-60.2%	-49.5%	-46.6%	-48.7%	-55.7%	-53.6%	-63.0%	-42.6%	-28.0%	-35.4%	-30.9%	-32.0%	-41.5%	-40.6%	-32.4%	-34.2%	-40.2%	-48.2%	-52.7%	-47.6%	-50.3%	-43.2%	-54.3%	-61.2%	-78.6%	-98.1%	-140.8%	-188.6%	-211.4%	-198.1%	-326.1%	-118.8%
ROA	—	—	—	—	-48.8%	-34.3%	-22.8%	-29.1%	-51.4%	-34.3%	-38.1%	-42.5%	-40.0%	-30.1%	-34.8%	-33.3%	-27.7%	-27.7%	-27.6%	-31.9%	-28.8%	-33.6%	-26.1%	-18.8%	-21.4%	-21.6%	-23.6%	-32.5%	-30.8%	-26.6%	-27.6%	-32.2%	-37.0%	-40.3%	-36.7%	-37.7%	-30.2%	-36.7%	-41.8%	-50.6%	-56.4%	-71.4%	-79.6%	-75.5%	-60.6%	-52.8%	-33.0%
Debt ratio	—	—	—	—	21.8%	19.1%	24.9%	29.7%	41.3%	47.7%	49.8%	47.6%	44.3%	38.7%	41.2%	42.1%	43.8%	42.7%	45.7%	43.6%	48.4%	49.7%	34.9%	26.1%	31.3%	18.2%	18.9%	18.2%	18.3%	17.7%	19.9%	21.9%	29.9%	31.6%	26.2%	28.6%	30.1%	33.1%	39.7%	46.4%	60.7%	76.3%	90.9%	93.3%	85.4%	97.0%	55.6%

EPS

Quarterly · US$

EPS US$-0.15

Show table：EPS

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.66	-0.73	-0.69	-0.43	0.12	-1.00	-0.86	-0.81	-0.57	-0.59	-0.74	-0.78	-0.81	-0.88	-0.71	-0.56	-0.55	-0.21	-0.76	-0.82	-0.75	-0.55	-0.92	-0.63	-0.28	0.00	-0.26	-0.15

Revenue & profit

Year-to-date · In mn (USD)

Revenue 14.7 mn Net income -43.2 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 237 mn Total liabilities 132 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -52.6 mn Investing -29.7 mn Financing 118 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -295.9% Net margin -293.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -118.8% ROA -33.0% Debt ratio 55.6%

EPS

Year-to-date · US$

EPS US$-0.41

Revenue & profit

Annual · In mn (USD)

Revenue 40.5 mn Net income -160 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	13.7	31.9	20.5	90.7	25.5	19.7	78.1	32.3	40.5
Operating income	-35.3	-97.2	-120	-114	-141	-135	-193	-226	-169	-251	-160
Net income	-72.9	-97.2	-120	-110	-134	-116	-192	-220	-153	-237	-160

Balance sheet

Annual · In mn (USD)

Total assets 187 mn Total liabilities 159 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	145	187	332	375	464	419	507	357	341	289	164
Total assets	149	229	373	420	509	573	677	514	499	342	187
Current liabilities	6.93	33.1	36.7	35.9	60.0	58.2	46.9	60.1	63.2	77.2	46.3
Total liabilities	32.6	94.6	165	184	246	179	124	154	150	207	159
Equity	-83.1	135	208	236	262	394	554	361	349	134	27.3

Cash flow

Annual · In mn (USD)

Operating -165 mn Investing 139 mn Financing 40.5 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-5.44	-50.3	-9.42	-45.7	-40.7	-180	-164	-177	-132	-210	-165
Investing	-1.43	-3.47	-184	-53.1	12.3	-141	-54.5	114	-3.73	162	139
Financing	139	97.2	155	86.9	132	224	282	1.28	118	56.0	40.5
Cash at period end	143	185	147	135	238	140	204	142	124	132	147

Profitability

Annual · %

Operating margin -394.9% Net margin -395.0%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	-873.6%	-356.1%	-686.4%	-148.6%	-756.1%	-1146.3%	-216.6%	-777.3%	-394.9%
Net margin	—	—	-876.5%	-344.3%	-651.4%	-127.8%	-753.6%	-1118.3%	-196.1%	-733.7%	-395.0%

Returns & leverage

Annual · %

ROE -198.1% ROA -60.6% Debt ratio 85.4%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-377.5%	-70.2%	-49.5%	-53.6%	-35.4%	-40.6%	-48.2%	-43.2%	-98.1%	-198.1%
ROA	-48.8%	-51.4%	-40.0%	-27.7%	-28.8%	-21.4%	-30.8%	-37.0%	-30.2%	-56.4%	-60.6%
Debt ratio	21.8%	41.3%	44.3%	43.8%	48.4%	31.3%	18.3%	29.9%	30.1%	60.7%	85.4%

EPS

Annual · US$

EPS US$-1.83

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	-2.00	-2.83	-3.21	-2.03	-2.88	-1.83

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Editas Medicine, Inc. (EDIT) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.